SEC Filing Summary: Xcyte Therapies, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by Xcyte Therapies, Inc. on April 1, 2005, reporting on events occurring on March 31, 2005. The filing serves to announce the company's financial results for the full year and fourth quarter ended December 31, 2004. The registrant is incorporated in Delaware with principal executive offices in Seattle, Washington.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K document.
Material Changes
The filing does not explicitly detail material changes versus prior periods within the text provided. It directs readers to the March 31, 2005 press release for the comparative analysis of the fourth quarter and full-year 2004 results.
Guidance, Outlook, and Risks
Management commentary, future guidance, risk factors, and contingencies are not included in the text of this Form 8-K. The document solely acts as a notification that the press release containing this information has been issued and is available as an exhibit.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 31, 2005) for specific revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Confirm any updates to clinical trial progress or product development milestones mentioned in the referenced exhibit.
- Check for any forward-looking statements or guidance provided in the press release that may differ from historical performance.